SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Nilotinib-d_6

Item No. 19280

CAS Registry No.:	1268356-17-7
Formal Name:	4-(methyl-d_3)-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide-2,3,6-d_3
MF:	$C_{28}H_{16}D_6F_3N_7O$
FW:	535.6
Chemical Purity:	≥98% (Nilotinib)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_6); ≤1% d0
Supplied as:	A solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nilotinib-d_6 is intended for use as an internal standard for the quantification of nilotinib (Item No. 10010422) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Nilotinib-d_6 is supplied as a solid. A stock solution may be made by dissolving the nilotinib-d_6 in the solvent of choice. Nilotinib-d_6 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of nilotinib-d_6 in these solvents is approximately 10 and 3 mg/ml, respectively.

Description

Nilotinib is a second generation tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of chronic myeloid leukemia (MLL) or Philadelphia chromosome acute lymphoblastic leukemia (Ph^+ ALL), even in patients who are resistant to the first generation drug, imatinib (Gleevec; Item Nos. 13139 | 18257).[1-4] Nilotinib is ~20-fold more potent than imatinib in inhibiting both wild-type and mutant Bcr/Abl (*e.g.*, IC_{50} = 15 *versus* 280 nM, respectively, for wild-type Bcr/Abl).[5]

References

1. Golemovic, M., Verstovsek, S., Giles, F., *et al.* AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has *in vitro* activity against imatinib-resistant chronic myeloid leukemia. *Clin. Cancer Res.* **11(13)**, 4941-4947 (2005).
2. Weisberg, E., Manley, P., Mestan, J., *et al.* AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. *Br. J. Cancer* **94(12)**, 1765-1769 (2006).
3. McFarland, K.L. and Wetzstein, G.A. Chronic myeloid leukemia therapy: Focus on second-generation tyrosine kinase inhibitors. *Cancer Control* **16(2)**, 132-140 (2009).
4. Kantarjian, H., Giles, F., Wunderle, L., *et al.* Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *N. Engl. J. Med.* **354(24)**, 2542-2551 (2006).
5. O'Hare, T., Walters, D.K., Stoffregen, E.P., *et al. In vitro* activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res.* **65(11)**, 4500-4505 (2005).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM